Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Cost of Revenue (2024 - 2025)

Celldex Therapeutics (CLDX) has 6 years of Cost of Revenue data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 23.92% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $6.0 million, up 6.88%, while the annual FY2025 figure was $6.0 million, 6.88% up from the prior year.
  • Cost of Revenue reached $1.2 million in Q4 2025 per CLDX's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.2 million in Q1 2025 and bottomed at $1.1 million in Q3 2025.